Form 4: Relay Therapeutics CFO Sells Shares to Cover Tax Obligations
SEC Form 4
Thomas Catinazzo, CFO of Relay Therapeutics, sold shares to cover income tax withholding obligations upon the vesting of restricted stock units.
Summary
- On March 27, 2025, Thomas Catinazzo, the Chief Financial Officer of Relay Therapeutics, sold 298 shares of common stock at a price of $2.84 per share to cover income tax withholding obligations.
- The sale was related to the vesting of 992 restricted stock units (RSUs) on March 26, 2025.
- Additionally, Catinazzo sold 4,566 shares at $2.84 per share pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on February 15, 2024.
- Following these transactions, Catinazzo beneficially owns 374,567 shares of Relay Therapeutics, which includes 254,354 shares underlying RSUs.
Sentiment
Score: 5
Explanation: The document describes routine transactions (tax obligation coverage and pre-planned sales) and doesn't indicate any significant positive or negative sentiment.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives. The use of a 10b5-1 trading plan is also a common practice to allow insiders to sell shares without being accused of insider trading.
Key Dates
| Date | Description |
|---|---|
| February 15, 2024 | Date the reporting person adopted a Rule 10b5-1 trading plan. |
| March 26, 2025 | Date of vesting of 992 shares of restricted stock units (RSUs). |
| March 27, 2025 | Date of the reported stock sales. |
| March 31, 2025 | Date of signature on the Form 4 filing. |
Keywords
Relay Therapeutics, RLAY, Catinazzo, Thomas, CFO, stock sale, Form 4, RSU, Rule 10b5-1, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.